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Purpose
Uveitis is an intraocular inflammatory disease that
accounts for 10-15% of all cases of total blindness in the
U.S. Although uveitis is more prevalent in adults, children
comprise approximately 5% of the uveitis population. The
most common etiologies of childhood uveitis are idio-
pathic, infectious, and rheumatologic. Idiopathic uveitis is
the most common cause of pediatric uveitis, while uveitis
associated with Juvenile Idiopathic Arthritis (JIA) is the
most common secondary cause. In 2005, the physicians of
Children’s Mercy’s Hospital created a dual Pediatric Rheu-
matology and Ophthalmology uveitis clinic for patients
with ocular inflammation requiring systemic immunosup-
pressant therapy. An ophthalmologist and rheumatologist
jointly evaluate each patient, and formulate a comprehen-
sive plan with the patient and family. To our knowledge,
this is the only pediatric uveitis clinic in the U.S. staffed by
the two subspecialties simultaneously. The aim of this
study was to determine if the characteristics of ocular
involvement differ between severe Idiopathic uveitis (IU)
and Secondary uveitis (SU).
Methods
A retrospective study of patients identified through a sche-
duling database that were evaluated in the uveitis clinic
from February 2005 to January 2010 was conducted. The
patients were subcategorized into two groups: IU and SU
based on the association or lack thereof with an underly-
ing autoimmune disease. Clinical characteristics recorded
included the involved site of inflammation, laterality, visual
acuity, complications defined as ocular structural damage
and pressure changes, concomitant number and type of
systemic medications needed to control inflammation, and
surgical interventions. Frequencies were compared
between groups using Chi-square analysis.
Results
Of the 41 patients seen over 456 encounters, 29 had IU
(71%) and 12 had SU (29%). Of the 12 SU patients, 10
(83.3%) had JIA, 6 oligoarticular and 4 polyarticular, 1
(8.3%) had Sarcoidosis, and 1 (8.3%) had Hashimoto’s.
Overall, the maximum number of systemic immunosup-
pressants used concomitantly was 4. Throughout the
course of treatment, patients received the following
medications: methotrexate (95%), TNF-a inhibitors
(34%), cyclosporine (22%), and mycophenolate mofitil
(15%). Surgical procedures over the course of follow-up,
most commonly vitrectomy and cataract removal, did
not differ significantly between groups.
Conclusion
No statistically significant differences were found in the
clinical characteristics and outcomes in patients with IU
and SU requiring systemic immunosuppressive therapy.
This could be due to a limited sample size, however,
these subsets of severe patients may be more phenotypi-
cally similar than previously recognized. This may allow
for the combination of both subtypes in future studies
of childhood uveitis.
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Table 1
At presentation: Idiopathic-29 Secondary-12 P value
Site of involvement
-Chronic anterior 18 (62%) 9 (75%)
-Pars planitis 7 (24%) 3 (25%)
- Panuveitis 2 (7%) 0 (0%)
-Acute anterior 1 (3%) 0 (0%)
-Chronic posterior 1 (3%) 0 (0%) 0.76
Laterality
- Bilateral 19 (66%) 10 (83%)
- Unilateral 10 (34%) 2 (17%) 0.25
Visual acuity >20/50 in worst eye 10 (36%) 2 (17%) 0.23
Visual acuity >20/200 in worst eye 7 (25%) 1 (8%) 0.23
Complications
-Synechiae 6 (21%) 2 (17%) 0.77
-Band keratopathy 4 (14%) 1 (8%) 0.63
-Ocular hypertension 5 (18%) 4 (33%) 0.28
-Cataracts 3 (10%) 0 (0%) 0.25
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